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ABSTRACT
Nowadays, cancer is one of the most common diseases in humans. Among all types, colorectal cancer (CRC) is one of the most serious types 
diagnosed in men after lung and prostate cancer while in women it occupies the second position after breast cancer worldwide. The risk factors 
such as obesity, sedentary lifestyle, bad nutritional habits (high in fats and proteins), smoking, and progressive aging are the cause of CRC. 
The acquisition of abnormal mutations leads to a consisting of many different arrangements of events during the tumor development process. 
Over the years, different approaches have been employed, in the treatment of cancer. These include chemotherapy, radiotherapy, surgery, and 
immunotherapy. Chemotherapy is routinely used for cancer treatment, but the toxicity of chemotherapeutics on healthy cells of the human body 
is obvious. This is the reason for discovering the new, natural origin, substances with potential cytostatic effects and less toxic side effects on the 
healthy cells. Medicinal plants have a special place in the management of cancer. Numerous cancer research studies have been conducted using 
traditional medicinal plants to discover new therapeutic agents with fewer side effects. In this review, we are describing two medicinal plants such 
as Actiniopteris radiata (Sw.) Link (Mayurashikha) and Terminalia pallida Brandis (Tella karaka) (endemic plant) which are available immensely in 
Chittoor District are used till today by the traditional herbal practitioners, tribal people is near to Talakona forest and Ayurvedic people for various 
diseases and also for CRC.
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INTRODUCTION
Colorectal cancer (CRC) is the fourth most common type of cancer 
in the world, with 1.3 million new cases each year and a 5-year 
prevalence rate of 3.2 million cases [1,2]. In 2012, there were an 
estimated 693,333 deaths due to CRC. The prevalence of CRC is higher 
in developed countries than in developing and undeveloped nations. 
Adults greater than 50 years are more prone to be affected by CRC, and 
incidence in males is greater than in females [3]. The CRC incidence 
and percentage vary from one place to another place in all over the 
world. In India, the incidence is higher in males; it is the fifth most 
common cancer following breast, cervix/uteri, lip/oral cavity, and lung 
cancer [1].
CRC is cancer that starts in either colon or rectum. It usually starts as 
a polyp in the intestinal mucosa exists as an initial benign lesion called 
adenoma that can transform into a malignant lesion depending on its 
histological presentation, and its size, of which 60% of cases are simple 
adenoma, and 40% are multiple adenomas. About 24% of patients with 
untreated polyps will develop cancer [4].
The clinical presentation of CRC depends on the location, size, as 
well as the presence or absence of metastasis. The symptoms include 
abdominal pain, alteration of chronic bowel habits, changes in bowel 
movements, involuntary weight loss, nausea, vomiting, malaise, 
anorexia, and abdominal distension [5]. Distal cancers cause evident 
rectal bleeding in comparison to proximal cancer that can give mixed 
blood with stool, so it tends to occulted, and in consequence, anemia 
may be presented as a secondary sign.
RISK FACTORS
The risk factors responsible for CRC are diet and westernized lifestyle; 
there is no specific food or another environmental agent that has been 
identified as an exact causative factor [6].
CRC identified types are hereditary nonpolyposis, familial adenomatous 
polyposis, inflammatory bowel diseases [7-10], human papillomaviruses, 
and acquired immunodeficiency syndrome [11]. Approximately 20% 
of CRC cases are associated with familial clustering, and patients with 
colorectal adenomas or invasive CRC are at increased risk for CRC [12-15].
The different lifestyle factors are associated with development of CRC 
including high alcohol consumption (60%) [16], high-fat diet poor in 
fiber, red meat, obesity, smoking (20%), lack of physical exercise [17], 
diabetes [18], older age, and family history (20%) [19].
STAGES OF COLORECTAL CANCER
CRC is classified under the Astler-Coller-Dukes system or tumor, node, 
and metastasis system established by the American Joint Committee on 
Cancer [20], which represents the stages of CRC by categories. The letter 
T represents the spread of tumors through the layers of the colonic or 
rectal wall, the letter N indicates if there is the propagation of tumors in 
the lymph node, and M indicates metastasis to distant organs [21]. The 
T, N, and M scores are combined to assign the CRC stages. There are five 
stages and they are numbered like I (1), II (2), III (3), or IV (4) (Table 1).
PATHOGENESIS
The bases of CRC hallmarks are genomic instability and inflammation. 
Genomic instability confers random mutations including chromosomal 
rearrangements, mutation errors in DNA, genes involved in the control 
of the cellular cycle, repair, and apoptosis or mutations in tumor 
suppressor gene such as adenomatous polyposis coli (APC), deleted 
in CRC (DCC), B-Raf proto-oncogene (BRAF), phosphatidylinositol-4, 
5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), protein 
kinase B, and tumor protein (TP53) or the presence oncogenes as 
Kirsten rat sarcoma (K-ras), and Catenin Beta 1, while the inflammatory 
state of premalignant and malignant lesions that are driven by cells of 
the immune system also fosters multiple hallmark functions [3].
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i6.33287
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Fearon and Vogelstein hypothesized that colorectal carcinogenesis is a 
multistep process in which genes are mutated in a specific order [22], 
resulting in the transition from normal mucosa to benign adenoma 
to severe dysplasia to carcinoma. The first in this process is the loss 
of APC tumor suppressor gene, which results in loss of DCC gene and 
activation of K-ras oncogene. This is followed by the inactivation of 
p53, leading to eventual carcinoma formation. This is in agreement 
with Knudson’s two-hit theory in which the carcinogenesis process 
is thought to result from an accumulation of two or more mutations 
that affect cell cycle control aberrations or other features of neoplastic 
development [23].
•	 First,	 the	 inactivation	or	 alteration	of	 the	APC	gene,	 i.e.,	 tumor	
suppressor gene can lead to the activation of the Wingless-type 
pathway, a common mechanism for initiating polyp to cancer 
progression sequence [24]
•	 Second,	mutations	of	oncogenes,	K-ras	virus	oncogene	homolog	
or B-Raf proto-oncogene, aberrantly activating the mitogen-
activated protein kinase signaling pathway leads to increase cell 
proliferation [25,26]
•	 Third,	 the	 inactivation	 of	 the	DCC	 gene	 is	 a	 late	 event	 in	 the	
carcinogenesis of CRC and has a role in metastasis [27]
•	 Lastly,	P53 is a tumor suppressor (transcriptional factor) that controls 
the cell cycle, apoptosis, and DNA repair mechanisms [28]. Hence, 
P53 mutations or the loss of its functionality and the frequency of 
alterations in the gene increases with the corresponding progression 
of the lesion [29].
Finally, the inflammatory proteins such as cyclooxygenase-2 (COX-2), 
inducible nitric oxide synthase (iNOS), and Cyclin D1 over expression 
lead to colorectal carcinogenesis
DIAGNOSIS
Current screening methods are targeted toward moderate risk 
population aged 50 or more [32].
•	 Medical	history:	The	causes	of	CRC	are	unknown.	By	collecting	the	
medical history of a patient include disease conditions/and certain 
medications, long-term usage lead to CRC will help to predict the 
causes of CRC
•	 Example:	 (a)	 Lynch	 syndrome	 also	 called	 hereditary	 non-
polyposis colon cancer is an inherited syndrome and familial 
adenomatous polyposis is a rare inherited syndrome that often 
leads to CRC
•	 Physical	exam:	Along	with	taking	medical	history,	it	is	also	important	
to examine the patient’s physical parameters to know about functions 
for the sign of disease
•	 Example:	Body	 temperature,	blood	pressure,	pulse	 rate,	 and	
respiration rate
Table 1: Tumor, node, and metastasis classification and stages of colorectal cancer
AICC stage TNM stage TNM stage criteria for colorectal cancer
Stage I T1 N0 M0 T1 Tumor invades submucosa
Stage I T2 N0 M0 T2 Tumor invades muscularis mucosa
Stage II-A T3 N0 M0 T3 Tumor invades subserosa or beyond
Stage II-B T4 N0 M0 T4 Tumor invades adjacent organs or perforates the visceral peritoneum
Stage III-A T1-2 N1 M0 N1 Metastasis to 1 to 3 regional lymph nodes. T1 or T2
Stage III-B T3-4 N1 M0 N1 Metastasis to 1 to 3 regional lymph nodes. T3 or T4
Stage III-C Any T, N2 M0 N2 Metastasis to 4 or more regional lymph nodes. Any T
Stage IV Any T, any N, M1 M1 Distant metastases present. Any T, any N
TNM: Tumor, node, and metastasis
Fig. 1: Colorectal cancer is a multi-step process in which genes are mutated in a specific sequence [30,31]
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•	 Total	colonoscopy:	It	is	a	procedure	in	which	the	morphology	of	large	
intestine	can	be	examined.	This	study	helps	in	finding	out	the	growth	
of polyps and any other disease related to the colon
•	 Blood	tests:	These	are	used	to	evaluate	the	disease	by	estimating	
biochemical parameters. (i) Complete blood count measures the 
number	of	blood	cells	 in	a	sample	and	(ii)	 chemistry	profile-CRC	
spreads cause high or low levels of chemicals in the blood
•	 Example:	High	carcinoembryonic	antigen	level
•	 Imaging	tests:	(i)	Computerized	tomography (CT) with contrast–CT 
takes many pictures a body part using X-rays, (ii) magnetic resonance 
image–uses	a	magnetic	field	and	radio	waves	to	take	pictures,	and	
(iii) positron emission tomography/CT-scan can show tumor size 
and	also	can	find	whether	a	tumor	is	a	metastasis	or	not
•	 Needle	biopsy:	Samples	of	tissue	or	fluid	removed	from	the	body	with	
a needle sent to a pathologist for cancer testing by performing the 
RAS mutation test, v-Raf murine sarcoma viral oncogene homolog B 




The treatment for CRC depends on whether the disease is nonmetastasis 
or metastasis. The mainstay curative treatment for patients with 
nonmetastasized tumors is surgery. However, the outcome is strongly 
related to the quality of surgery [33,34] the quality of preoperative staging 
and treatment selection. Local recurrences after the colon and rectal 
surgery can be minimized using short-course radiotherapy [35-37], 
although long-term therapy showed no effect on overall survival for 
this approach [38]. Neoadjuvant radiotherapy/chemoradiotherapy) 
can be proposed for patients with unfavorable T3 rectal tumors. The 
chemotherapy backbone for first-line treatment of metastatic disease 
is typically a combination of leucovorin, 5-fluorouracil, and either 
oxaliplatin or irinotecan (Adjuvant chemotherapy) [39]. Some of the 
researchers have focused on this adjuvant chemotherapy drugs to 
overcome therapy resistance, reduce dose requirements, drug-induced 
adverse effects and increase cytotoxic effects using histone deacetylase 
inhibitors (Vorinostat, romidepsin, panobinostat, and belinostat) [40]. 
These treatment methods are not as effective in treating cancer cases in 
the metastasis stage. Cancer treatment failure, through chemotherapy, 
can happen because of the low selectivity of the cytotoxic and 
uncertainty of the molecular targeted [41]. Chemotherapy can put the 
patient under a lot of strain and further damage their health. Hence, 
many of the researchers have to focus on using alternative therapies 
against cancer with low side effects.
Nowadays, the most important problem in cancer treatment is 
destroying tumor cells in the presence of natural cells, without 
damaging natural cells. To prepare anticancer medicines from 
natural resources such as plants, testing cytotoxic compounds, and 
screening raw extracts of plants are necessary [42]. Therefore, the 
availability of natural products with higher effectiveness and lower 
side effects is desired [43]. Medicinal herbs are important for cancer 
treatment due to their multiple chemical compounds for discovering 
new active materials against cancer [44]. These compounds are called 
secondary metabolites. Alkaloids, terpenoids, flavonoids, pigments, 
and tannins are important constituents of these compounds. Secondary 
metabolites have biologic effects such as anti-inflammatory, anticancer, 
contraceptive, and different effects on hematopoietic cells [45], 
lipids [46], and cardiovascular systems [47]. Different improvements 
are reported in common treatments of cancer by finding secondary 
compounds of natural products and medicinal herbs. It is believed 
that anticancer effects of plants develop by suppressing cancer’s 
stimulating enzymes, repairing DNA, stimulating the production of 
antitumor enzymes in the cell, increasing body immunity, and inducing 
antioxidant effects [48,49].
The different researches and studies have been proved the positive 
effect of plants in curing diabetes, fertility, and sterility, thyroid 
disorders, anemia, psychological disorder, etc. Finding plants that 
replace chemotherapy and cumbersome cures of cancer with cytotoxic 
effects are necessary.
In this review, we chose Actiniopteris radiata and Terminalia pallida 
ayurvedic plants to describe the mechanism of action for the treatment of 
CRC. Mayurashikha (A. radiata) is an ayurvedic herb and a tiny terrestrial 
fern found throughout India. It is also called as Peacock’s tail. A. radiata 
(Sw.) Link. belonging to the family Polypodiaceae. It is also found in 
different places such as Burma, Sri Lanka, Afghanistan, Persia, Arabia, 
Yemen,	South	Eastern	Egypt,	Tropical	Africa,	Australia,	and	Madagascar.	
The whole part of the plant is used in wounds, intestinal worms as a 
cooling agent in syphilis, rickettsiae, piles, leukorrhea, typhoid [50], 
cough, high blood pressure, tuberculosis, asthma, fever, leprosy, and 
hair growth [51]. The leaves of the plant are used for aphrodisiac [52], 
to increase the potency in women [52-54], as leukorrhea, as 
fertility [55,56], in irregular menstrual period, for conception, and birth 
control [51]. The stem of this plant is used in diarrhea [56,57].
The chemical constituents such as flavonoid glycoside (Quercetin-
3-rutinoside),	 steroidal	 compounds	 (β-sitosterol,	 β-sitosterol	
palmitate,	 and	 β-sitosterol-D-glucoside),	 alkane	 hydrocarbon	
chains (hentriacontane and hentriacontanol) [58], and glycosides 
(2-(3, 4-O–diglucos cinnamoyl)– 4– hydroxyl furan and 1-Heptaloyl, 
8-hexyl, 3-(O–diglucos), 10–methyl, 9, 10–dihydro naphthalene) are 
used [59]. The other constituents are glucose, fructose, flavonoids, 
alkaloids, tannins, phenols, saponins, quinines, terpenoids, coumarins, 
β-cyanin,	and	triterpenoids	[60].
Fig. 2: Structure of Rutin-flavonoid glycoside (quercetin-3-
rutinoside)
Fig. 3: Actiniopteris radiata (Sw.) Link (Mayurashikha)
Fig. 4: Terminalia pallida Brandis (Tella karaka) (Endemic plant)
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The plant extract possesses different research activities such 
as analgesic activity [61], antihistaminic and anti-cholinergic 
activity [62], antifertility [63], antitubercular [64], antibacterial [65], 
anthelmintic [66], antifungal [67], wound healing [61], antistress 
and antiallergic effects [68], antioxidant and radical scavenging 
activity [69,70], hepatoprotective activity [71] diuretic, anti-
inflammatory, and antidiabetic activity [72]
T. pallida Brandis is herb from the family Combretaceae. It is a semi-
evergreen tree group. Leaf fall and flushing events occur during the 
pre-monsoon season; leaf flushing extends into the monsoon season. 
The flowers are bisexual and obligately outcrossed and enforced by 
self-incompatibility. Fruits fall to the ground when mature and dry in 
the presence of wind. The fallen fruits are scattered by rainwater, and 
the seeds germinate and establish seedlings depending on the soil 
status [73]. It is one of the oldest medicinal herbs of India, which is an 
ingredient of Indian Ayurvedic drug “Triphala” used for the treatment of 
digestion and liver disorders. In Indian traditional system of medicine, 
the fruits are also used in the treatment of hepatic disorders and the 
treatment of diabetes by tribal people [74]. The leaf is used for treating 
skin blisters and skin diseases, whereas the stem bark is used as a 
diuretic and for swellings. The fruit is used as an anti-pyretic, purgative, 
for diarrhea, peptic ulcers, diabetes, venereal diseases, cough, cold, 
dysentery, fissures, and cracks; and in tanning and dying. Bark powder is 
applied externally and can be taken internally as an anti-inflammatory 
agent. Fruit powder is given orally to cure peptic ulcer fissure and to 
clear the harshness of voice [75-77].
The reported biological activities of Terminalia pallida such as anti-
oxidant activity and hepatoprotective potential [78], analgesic and 
anti-pyretic activity [75], anti-diabetic activity [76], anti-atherogenic 
and anti-hyperlipidemic activities of fruits [77], anti-ulcer activity [79], 
anti-bacterial activity [80], phytochemical evaluation and antimicrobial 
studies [81]. This plant has many important phytoconstituents such 
as gallotannic acid, bellericanin, gallic acid, ellagic acid, termilignan, 
thannin lignin, flavones and anolignan B, tannins, ethyl gallate, ellagic 
acid, gallonyl glucose, and chebulagic acid, phenyllemblin, beta-
sitosterol, mannitol, rhamnose, and glucose [75-77,79,81]
Medicinal plants are representing a wide variety of phytochemicals 
with pharmaceutical potential such as phenolic acids, flavonoids, 
steroids, terpenoids, and triterpenoids. Polyphenols such as flavonoids 
and phenolic acids have been reported to have many pharmacological 
activities, such as antioxidant, anti-inflammatory, anticarcinogenic, 
antiviral, or anti-allergic effects [82-86]. Among anticancer and 
cancer-preventing drugs, flavonoids are the most studied ones. These 
compounds can interfere with specific stages of the carcinogenic 
process, inhibit cell proliferation, and induce apoptosis in several types 
of cancer cells [87-91]. Flavonoids exhibit a good antioxidant activity 
by inhibiting reactive oxygen species generation/affecting the activity 
of sundry detoxifying enzymes, such as COXs, Lipoxygenases, and 
iNOS [92-94]. This antioxidant capacity of flavonoids could possibly 
account for their anticancer potency. Flavonoids have also been found 
to influence epigenetic alterations by chromatin remodeling [95,96]. 
Hashemzaei et al., 2017 [81], were reported and proved that quercetin 
(belongs to polyphenolic flavonoid) is a potent anticancer agent in 
in vitro and in vivo cancer studies. In particular, it has been reported 
that quercetin at various concentrations, suppresses tumor growth of 
various cancer cell lines, including breast, colorectal, stomach, head and 
neck, lung, ovarian, melanoma, and leukemia [97-107]. Mayurashikha 
contains major phytoconstituent is rutin (Quercetin-3-glycoside) [58] 
and T. pallida with a major constituent is phenolic acids [81]. Due to the 
presence of phytoconstituents, in these plants may show the antioxidant 
and anticancer property that happens maybe by inducing apoptosis 
initiation, ATP-dependent chromatin remodeling, reduce COX-2 
overexpression and DNA methylation, histone modification, inhibition 
of misregulation of miRNA, and tumor angiogenesis and also can modify 
the different cellular signaling pathways involved in cell proliferation.
The above two medicinal plants will be the plan to do research work for 
anti-CRC activity in vitro and in vivo cancer models.
CONCLUSION
CRC is a leading problem globally, especially in developing countries 
and also in developed countries because many of the people migrated 
from village to town; changing their lifestyles and food habits. Majority 
food intake and lifestyle habits are the risk factors for the development 
of cancer in the colon. Management of CRC by surgery followed adjuvant 
therapy (Radiotherapy and chemotherapy) produce high toxic effects 
which can be minimized with supplementation of medicinal plants 
(Ayurveda). Medicinal plants have a major role in the treatment of 
different ailments like cancer because they have major nutritive values 
and antioxidant properties. Mayurashikha (A. radiata) and T. pallida 
Brandis are two medicinal plants with specific active constituents that 
may show anti-CRC property.
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